MicroRNAs: Potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 1-10

  He, Ming Liang ^a   Luo, Millore X M ^a   Lin, Marie C ^b   Kung, Hsiang fu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Biomarkers; MicroRNAs; Nasopharyngeal carcinoma; Therapeutic targets

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; TUMOR MARKER; VIRUS RNA;

BLOOD LEVEL; CANCER GENE THERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CORRELATION ANALYSIS; DISEASE MARKER; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; HUMAN; MICROENVIRONMENT; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TUMOR BIOPSY;

HUMAN HERPESVIRUS 4;

EID: 80053537922     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.09.001     Document Type: Review

References (159)

1. Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006, 85:74.
2. Razak A.R., Siu L.L., Liu F.F., Ito E., O'Sullivan B., Chan K. Nasopharyngeal carcinoma: the next challenges. Eur. J. Cancer 2010, 46:1967-1978.
3. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Cao S.M., Simons M.J., Qian C.N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 2011, 30:114-119.
6. Boysen T., Friborg J., Andersen A., Poulsen G.N., Wohlfahrt J., Melbye M. The Inuit cancer pattern-the influence of migration. Int. J. Cancer 2008, 122:2568-2572.
7. Nielsen L.G., Frisch M., Melbye M. Cancer risk in a cohort of Danes working in Greenland. Scand. J. Soc. Med. 1997, 25:44-49.
8. Chang E.T., Adami H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1765-1777.
9. Pathmanathan R., Prasad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995, 333:693-698.
10. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 2002, 12:451-462.
11. Xiong W., Zeng Z.Y., Xia J.H., Xia K., Shen S.R., Li X.L., Hu D.X., Tan C., Xiang J.J., Zhou J., Deng H., Fan S.Q., Li W.F., Wang R., Zhou M., Zhu S.G., Lu H.B., Qian J., Zhang B.C., Wang J.R., Ma J., Xiao B.Y., Huang H., Zhang Q.H., Zhou Y.H., Luo X.M., Zhou H.D., Yang Y.X., Dai H.P., Feng G.Y., Pan Q., Wu L.Q., He L., Li G.Y. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004, 64:1972-1974.
12. Feng B.J., Huang W., Shugart Y.Y., Lee M.K., Zhang F., Xia J.C., Wang H.Y., Huang T.B., Jian S.W., Huang P., Feng Q.S., Huang L.X., Yu X.J., Li D., Chen L.Z., Jia W.H., Fang Y., Huang H.M., Zhu J.L., Liu X.M., Zhao Y., Liu W.Q., Deng M.Q., Hu W.H., Wu S.X., Mo H.Y., Hong M.F., King M.C., Chen Z., Zeng Y.X. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet. 2002, 31:395-399.
13. Bei J.X., Li Y., Jia W.H., Feng B.J., Zhou G., Chen L.Z., Feng Q.S., Low H.Q., Zhang H., He F., Tai E.S., Kang T., Liu E.T., Liu J., Zeng Y.X. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat. Genet. 2011, 42:599-603.
14. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
15. Knox P.G., Li Q.X., Rickinson A.B., Young L.S. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus:cell interaction observed in nasopharyngeal carcinoma. Virology 1996, 215:40-50.
16. Chen C.L., Wen W.N., Chen J.Y., Hsu M.M., Hsu H.C. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology 1993, 36:91-98.
17. Andersson-Anvret M., Forsby N., Klein G., Henle W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int. J. Cancer 1977, 20:486-494.
18. Tsai S.T., Jin Y.T., Su I.J. Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histologic subtypes. Cancer 1996, 77:231-236.
19. Brooks L., Yao Q.Y., Rickinson A.B., Young L.S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 1992, 66:2689-2697.
20. Eliopoulos A.G., Stack M., Dawson C.W., Kaye K.M., Hodgkin L., Sihota S., Rowe M., Young L.S. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997, 14:2899-2916.
21. Paramita D.K., Fatmawati C., Juwana H., van Schaijk F.G., Fachiroh J., Haryana S.M., Middeldorp J.M. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J. Med. Virol. 2011, 83:665-678.
22. Munz C., Moormann A. Immune escape by Epstein-Barr virus associated malignancies. Semin. Cancer Biol. 2008, 18:381-387.
23. Middeldorp J.M., Pegtel D.M. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin. Cancer Biol. 2008, 18:388-396.
24. Cvitkovic E., Bachouchi M., Boussen H., Busson P., Rousselet G., Mahjoubi R., Flores P., Tursz T., Armand J.P., Azli N. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J. Clin. Oncol. 1993, 11:2434-2442.
25. Le Q.T. Nasopharyngeal and oropharyngeal carcinomas: target delineation, therapy delivery and stereotactic boost procedures with intensity-modulated/image-guided radiation therapy. Front. Radiat. Ther. Oncol. 2007, 40:208-231.
26. Arango B.A., Castrellon A.B., Perez C.A., Raez L.E., Santos E.S. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert. Rev. Anticancer. Ther. 2010, 10:377-386.
27. Sheng L., Shui Y., Shen L., Wei Q. Effect of patient-related delay in diagnosis on the extent of disease and prognosis in nasopharyngeal carcinoma. Am. J. Rhinol. 2008, 22:317-320.
28. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
29. Yau T.K., Lee A.W., Wong D.H., Pang E.S., Ng W.T., Yeung R.M., Soong I.S. Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:1004-1010.
30. Yi Z., Yuxi L., Chunren L., Sanwen C., Jihneng W., Jisong Z., Huijong Z. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 1980, 13:162-168.
31. Vlantis A.C., Bower W.F., Woo J.K., Tong M.C., van Hasselt C.A. Endoscopic assessment of the nasopharynx: an objective score of abnormality to predict the likelihood of malignancy. Ann. Otol. Rhinol. Laryngol. 2010, 119:77-81.
32. Ho J.H. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1978, 4:182-198.
33. Wei Y.S., Zheng Y.H., Liang W.B., Zhang J.Z., Yang Z.H., Lv M.L., Jia J., Zhang L. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 2008, 112:544-551.
34. Chang K.P., Wu C.C., Chen H.C., Chen S.J., Peng P.H., Tsang N.M., Lee L.Y., Liu S.C., Liang Y., Lee Y.S., Hao S.P., Chang Y.S., Yu J.S. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010, 10:2644-2660.
35. Tang F., Xie C., Huang D., Wu Y., Zeng M., Yi L., Wang Y., Mei W., Cao Y., Sun L. Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy. Clin. Biochem. 2011, 44:711-718.
36. Wong B.C., Chan K.C., Chan A.T., Leung S.F., Chan L.Y., Chow K.C., Lo Y.M. Reduced plasma RNA integrity in nasopharyngeal carcinoma patients. Clin. Cancer Res. 2006, 12:2512-2516.
37. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., Harijadi, Fachiroh J., Paramita D.K., Tan I.B., Haryana S.M., Middeldorp J.M. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J. Clin. Microbiol. 2005, 43:3066-3073.
38. Wang W.Y., Twu C.W., Chen H.H., Jan J.S., Jiang R.S., Chao J.Y., Liang K.L., Chen K.W., Wu C.T., Lin J.C. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin. Cancer Res. 2010, 16:1016-1024.
39. Shao J.Y., Zhang Y., Li Y.H., Gao H.Y., Feng H.X., Wu Q.L., Cui N.J., Cheng G., Hu B., Hu L.F., Ernberg I., Zeng Y.X. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer. Res. 2004, 24:4059-4066.
40. Pak M.W., To K.F., Lo Y.M., Chan L.Y., Tong J.H., Lo K.W., van Hasselt C.A. Nasopharyngeal carcinoma in situ (NPCIS)-pathologic and clinical perspectives. Head Neck 2002, 24:989-995.
41. Lo Y.M., Chan A.T., Chan L.Y., Leung S.F., Lam C.W., Huang D.P., Johnson P.J. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000, 60:6878-6881.
42. Karanikiotis C., Daniilidis M., Karyotis N., Bakogiannis C., Economopoulos T., Murray S., Papamichael D., Samantas E., Nikolaou A., Skoura L., Tselis N., Zamboglou N., Fountzilas G. HLA Class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma. Strahlenther. Onkol. 2008, 184:325-331.
43. Leung S.F., Zee B., Ma B.B., Hui E.P., Mo F., Lai M., Chan K.C., Chan L.Y., Kwan W.H., Lo Y.M., Chan A.T. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J. Clin. Oncol. 2006, 24:5414-5418.
44. Lin J.C., Wang W.Y., Chen K.Y., Wei Y.H., Liang W.M., Jan J.S., Jiang R.S. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 2004, 350:2461-2470.
45. Ji M.F., Yu Y.L., Cheng W.M., Zong Y.S., Ng P.S., Chua D.T., Ng M.H. Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin. J. Cancer 2011, 30:120-123.
46. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
47. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
48. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57:84-91.
49. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
50. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
51. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J. Pathol. 2011, 223:102-115.
52. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
53. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
54. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
55. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
56. Molnar A., Schwach F., Studholme D.J., Thuenemann E.C., Baulcombe D.C. miRNAs control gene expression in the single-cell alga Chlamydomonas reinhardtii. Nature 2007, 447:1126-1129.
57. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., John B., Enright A.J., Marks D., Sander C., Tuschl T. Identification of virus-encoded microRNAs. Science 2004, 304:734-736.
58. Nakahara K., Carthew R.W. Expanding roles for miRNAs and siRNAs in cell regulation. Curr. Opin. Cell Biol. 2004, 16:127-133.
59. Moss E.G., Poethig R.S. MicroRNAs: something new under the sun. Curr. Biol. 2002, 12:R688-R690.
60. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J. Pathol. 2010, 223:102-115.
61. Li M., Li J., Ding X., He M., Cheng S.Y. microRNA and cancer. AAPS J. 2010, 12:309-317.
62. Grundhoff A., Sullivan C.S. Virus-encoded microRNAs. Virology 2011, 411:325-343.
63. Sullivan C.S., Ganem D. MicroRNAs and viral infection. Mol. Cell 2005, 20:3-7.
64. Nair V., Zavolan M. Virus-encoded microRNAs: novel regulators of gene expression. Trends Microbiol. 2006, 14:169-175.
65. Scaria V., Hariharan M., Pillai B., Maiti S., Brahmachari S.K. Host-virus genome interactions: macro roles for microRNAs. Cell. Microbiol. 2007, 9:2784-2794.
66. Yeung M.L., Bennasser Y., Jeang K.T. miRNAs in the biology of cancers and viral infections. Curr. Med. Chem. 2007, 14:191-197.
67. Choy E.Y., Siu K.L., Kok K.H., Lung R.W., Tsang C.M., To K.F., Kwong D.L., Tsao S.W., Jin D.Y. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J. Exp. Med. 2008, 205:2551-2560.
68. Boss I.W., Plaisance K.B., Renne R. Role of virus-encoded microRNAs in herpesvirus biology. Trends Microbiol. 2009, 17:544-553.
69. David M. Interferons and microRNAs. J. Interferon Cytokine Res. 2010, 30:825-828.
70. Meckes D.G., Shair K.H., Marquitz A.R., Kung C.P., Edwards R.H., Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20370-20375.
71. Barth S., Meister G., Grasser F.A. EBV-encoded miRNAs. Biochim. Biophys. Acta 2011, 10.1016/j.bbagrm.2011.1005.1010.
72. Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 1:702-703.
73. Epstein M.A. Historical background. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356:413-420.
74. Cossart Y.E., Field A.M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1:848.
75. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:3812-3815.
76. Thorley-Lawson D.A. EBV the prototypical human tumor virus-just how bad is it?. J. Allergy Clin. Immunol. 2005, 116:251-261. (quiz 262).
77. Masucci M.G., Ernberg I. Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol. 1994, 2:125-130.
78. Miyashita E.M., Yang B., Lam K.M., Crawford D.H., Thorley-Lawson D.A. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995, 80:593-601.
79. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 2001, 1:75-82.
80. Sample J., Henson E.B., Sample C. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 1992, 66:4654-4661.
81. Casola S., Otipoby K.L., Alimzhanov M., Humme S., Uyttersprot N., Kutok J.L., Carroll M.C., Rajewsky K. B cell receptor signal strength determines B cell fate. Nat. Immunol. 2004, 5:317-327.
82. Niller H.H., Salamon D., Rahmann S., Ilg K., Koroknai A., Banati F., Schwarzmann F., Wolf H., Minarovits J. A 30kb region of the Epstein-Barr virus genome is colinear with the rearranged human immunoglobulin gene loci: implications for a "ping-pong evolution" model for persisting viruses and their hosts. A review. Acta Microbiol. Immunol. Hung. 2004, 51:469-484.
83. Ackermann M. Pathogenesis of gammaherpesvirus infections. Vet. Microbiol. 2006, 113:211-222.
84. Lerner M.R., Andrews N.C., Miller G., Steitz J.A. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:805-809.
85. Chen H.L., Lung M.M., Sham J.S., Choy D.T., Griffin B.E., Ng M.H. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology 1992, 191:193-201.
86. Rechavi O., Erlich Y., Amram H., Flomenblit L., Karginov F.V., Goldstein I., Hannon G.J., Kloog Y. Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs. Genes Dev. 2009, 23:1971-1979.
87. Chen S.J., Chen G.H., Chen Y.H., Liu C.Y., Chang K.P., Chang Y.S., Chen H.C. Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. Plos One 2010, 5.
88. Cosmopoulos K., Pegtel M., Hawkins J., Moffett H., Novina C., Middeldorp J., Thorley-Lawson D.A. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J. Virol. 2009, 83:2357-2367.
89. Zhu J.Y., Pfuhl T., Motsch N., Barth S., Nicholls J., Grasser F., Meister G. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J. Virol. 2009, 83:3333-3341.
90. Wong A.M., Kong K.L., Tsang J.W., Kwong D.L., Guan X.Y. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2011, 10.1002/cncr.26309.
91. Cullen B.R. Viral and cellular messenger RNA targets of viral microRNAs. Nature 2009, 457:421-425.
92. Lo A.K., To K.F., Lo K.W., Lung R.W., Hui J.W., Liao G., Hayward S.D. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16164-16169.
93. Barth S., Pfuhl T., Mamiani A., Ehses C., Roemer K., Kremmer E., Jaker C., Hock J., Meister G., Grasser F.A. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res. 2008, 36:666-675.
94. Lung R.W., Tong J.H., Sung Y.M., Leung P.S., Ng D.C., Chau S.L., Chan A.W., Ng E.K., Lo K.W., To K.F. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009, 11:1174-1184.
95. Kim do N., Chae H.S., Oh S.T., Kang J.H., Park C.H., Park W.S., Takada K., Lee J.M., Lee W.K., Lee S.K. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J. Virol. 2007, 81:1033-1036.
96. Nachmani D., Stern-Ginossar N., Sarid R., Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009, 5:376-385.
97. Iizasa H., Wulff B.E., Alla N.R., Maragkakis M., Megraw M., Hatzigeorgiou A., Iwakiri D., Takada K., Wiedmer A., Showe L., Lieberman P., Nishikura K. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J. Biol. Chem. 2010, 285:33358-33370.
98. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., Ramos J.C., Luz E., Pedroso C., Manrique M., Toomey N.L., Brites C., Dittmer D.P., Harrington W.J. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 2008, 68:1436-1442.
99. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5874-5878.
100. Chen H.C., Chen G.H., Chen Y.H., Liao W.L., Liu C.Y., Chang K.P., Chang Y.S., Chen S.J. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br. J. Cancer 2009, 100:1002-1011.
101. Li T., Chen J.X., Fu X.P., Yang S., Zhang Z., Chen Kh H., Li Y. microRNA expression profiling of nasopharyngeal carcinoma. Oncol. Rep. 2011, 25:1353-1363.
102. Zhang Z., Sun D., Van do N., Tang A., Hu L., Huang G. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int. J. Cancer 2007, 120:32-38.
103. Zeng Z.Y., Zhou Y.H., Zhang W.L., Xiong W., Fan S.Q., Li X.L., Luo X.M., Wu M.H., Yang Y.X., Huang C., Cao L., Tang K., Qian J., Shen S.R., Li G.Y. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum. Pathol. 2007, 38:120-133.
104. Yip W.K., Leong V.C., Abdullah M.A., Yusoff S., Seow H.F. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol. Rep. 2008, 19:319-328.
105. Yang H.J., Cho Y.J., Kim H.S., Chang M.S., Sung M.W., Kim W.H. Association of p53 and BCL-2 expression with Epstein-Barr virus infection in the cancers of head and neck. Head Neck 2001, 23:629-636.
106. Liu H., Peng C., Zhou M., Zhou J., Shen S., Zhou H., Xiong W., Luo X., Peng S., Niu Z., Ouyang J., Li X., Li G. Cloning and characterization of the BRD7 gene promoter. DNA Cell Biol. 2006, 25:346-358.
107. Xu X., Yang H., Huo X. Expression and significance of PTEN in nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004, 18:658-659.
108. Liu H., Zhou M., Luo X., Zhang L., Niu Z., Peng C., Ma J., Peng S., Zhou H., Xiang B., Li X., Li S., He J., Li G. Transcriptional regulation of BRD7 expression by Sp1 and c-Myc. BMC Mol. Biol. 2008, 9:111.
109. Wang X., Xiao J., Zhao S., Tian Y., Wang G. Expression of telomerase subunits and its relationship with telomerase activity in nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi 2001, 81:553-556.
110. Wang S.S., Guan Z.Z., Xiang Y.Q., Wang B., Lin T.Y., Jiang W.Q., Zhang L., Zhang H.Z., Hou J.H. Significance of EGFR and p-ERK expression in nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 2006, 28:28-31.
111. Thornburg N.J., Pathmanathan R., Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003, 63:8293-8301.
112. Shi W., Bastianutto C., Li A., Perez-Ordonez B., Ng R., Chow K.Y., Zhang W., Jurisica I., Lo K.W., Bayley A., Kim J., O'Sullivan B., Siu L., Chen E., Liu F.F. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int. J. Cancer 2006, 119:2467-2475.
113. Sheu L.F., Chen A., Lee H.S., Hsu H.Y., Yu D.S. Cooperative interactions among p53, bcl-2 and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol. Int. 2004, 54:475-485.
114. Segawa Y., Oda Y., Yamamoto H., Shiratsuchi H., Hirakawa N., Komune S., Tsuneyoshi M. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. Oncol. Rep. 2009, 21:1197-1202.
115. Qian C.N., Guo X., Cao B., Kort E.J., Lee C.C., Chen J., Wang L.M., Mai W.Y., Min H.Q., Hong M.H., Vande Woude G.F., Resau J.H., Teh B.T. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002, 62:589-596.
116. Morrison J.A., Gulley M.L., Pathmanathan R., Raab-Traub N. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 2004, 64:5251-5260.
117. Makitie A.A., MacMillan C., Ho J., Shi W., Lee A., O'Sullivan B., Payne D., Pintilie M., Cummings B., Waldron J., Warde P., Irish J., Brown D., Gilbert R., Gullane P., Liu F.F., Kamel-Reid S. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin. Cancer Res. 2003, 9:2177-2184.
118. Luo J., Xiao J., Tao Z., Li X. Detection of c-myc gene expression in nasopharyngeal carcinoma by nonradioactive in situ hybridization and immunohistochemistry. Chin. Med. J. (Engl.) 1997, 110:229-232.
119. Lu Q.L., Elia G., Lucas S., Thomas J.A. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer 1993, 53:29-35.
120. Lu J., Chua H.H., Chen S.Y., Chen J.Y., Tsai C.H. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res. 2003, 63:256-262.
121. Lo K.W., Cheung S.T., Leung S.F., van Hasselt A., Tsang Y.S., Mak K.F., Chung Y.F., Woo J.K., Lee J.C., Huang D.P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 1996, 56:2721-2725.
122. Lo A.K., Lo K.W., Tsao S.W., Wong H.L., Hui J.W., To K.F., Hayward D.S., Chui Y.L., Lau Y.L., Takada K., Huang D.P. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 2006, 8:173-180.
123. Liu J.P., Cassar L., Pinto A., Li H. Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma. Cell Res. 2006, 16:809-817.
124. Li Y.H., Hu C.F., Shao Q., Huang M.Y., Hou J.H., Xie D., Zeng Y.X., Shao J.Y. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J. Transl. Med. 2008, 6:1.
125. Leong J.L., Loh K.S., Putti T.C., Goh B.C., Tan L.K. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004, 114:153-157.
126. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 2002, 8:131-137.
127. Krishna S.M., James S., Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res. 2006, 115:85-90.
128. Jayasurya A., Bay B.H., Yap W.M., Tan N.G. Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br. J. Cancer 2000, 82:1198-1203.
129. Hwang C.F., Su C.Y., Huang S.C., Huang C.C., Fang F.M., Lui C.C., Chang H.W., Cho C.L. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett. 2003, 189:231-236.
130. Hwang C.F., Cho C.L., Huang C.C., Wang J.S., Shih Y.L., Su C.Y., Chang H.W. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann. Oncol. 2002, 13:1246-1251.
131. Hui E.P., Chan A.T., Pezzella F., Turley H., To K.F., Poon T.C., Zee B., Mo F., Teo P.M., Huang D.P., Gatter K.C., Johnson P.J., Harris A.L. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 2002, 8:2595-2604.
132. Hui A.B., Lo K.W., Kwong J., Lam E.C., Chan S.Y., Chow L.S., Chan A.S., Teo P.M., Huang D.P. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol. Carcinog. 2003, 38:170-178.
133. Huang G.W., Mo W.N., Kuang G.Q., Nong H.T., Wei M.Y., Sunagawa M., Kosugi T. Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 2001, 111:1465-1471.
134. Fujii M., Yamashita T., Ishiguro R., Tashiro M., Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 2002, 29:175-181.
135. Fendri A., Khabir A., Mnejja W., Sellami-Boudawara T., Daoud J., Frikha M., Ghorbel A., Gargouri A., Mokdad-Gargouri R. PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci. 2009, 100:2034-2039.
136. Crook T., Nicholls J.M., Brooks L., O'Nions J., Allday M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 2000, 19:3439-3444.
137. Chow L.S., Lo K.W., Kwong J., To K.F., Tsang K.S., Lam C.W., Dammann R., Huang D.P. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int. J. Cancer 2004, 109:839-847.
138. Chou C.C., Chou M.J., Tzen C.Y. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med. Oncol. 2009, 26:322-326.
139. Cheung H.W., Ching Y.P., Nicholls J.M., Ling M.T., Wong Y.C., Hui N., Cheung A., Tsao S.W., Wang Q., Yeun P.W., Lo K.W., Jin D.Y., Wang X. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol. Carcinog. 2005, 43:237-245.
140. Chan C.M., Ma B.B., Hui E.P., Wong S.C., Mo F.K., Leung S.F., Kam M.K., Chan A.T. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma-a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol. 2007, 43:373-378.
141. Bar-Sela G., Kuten A., Ben-Eliezer S., Gov-Ari E., Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod. Pathol. 2003, 16:1035-1040.
142. Lo K.W., To K.F., Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5:423-428.
143. Chou J., Lin Y.C., Kim J., You L., Xu Z., He B., Jablons D.M. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 2008, 30:946-963.
144. Wong T.S., Man O.Y., Tsang C.M., Tsao S.W., Tsang R.K., Chan J.Y., Ho W.K., Wei W.I., To V.S. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J. Cancer Res. Clin. Oncol. 2010, 137:415-422.
145. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., Chen Y.C., Peng Y., Yao K.T., Kung H.F., Li X.P. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71:225-233.
146. Alajez N.M., Shi W., Hui A.B., Bruce J., Lenarduzzi M., Ito E., Yue S., O'Sullivan B., Liu F.F. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 2011, 1:e85.
147. Xia H., Cheung W.K., Sze J., Lu G., Jiang S., Yao H., Bian X.W., Poon W.S., Kung H.F., Lin M.C. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J. Biol. Chem. 2010, 285:36995-37004.
148. Xia H., Ng S.S., Jiang S., Cheung W.K., Sze J., Bian X.W., Kung H.F., Lin M.C. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun. 2009, 391:535-541.
149. Zhang L., Deng T., Li X., Liu H., Zhou H., Ma J., Wu M., Zhou M., Shen S., Niu Z., Zhang W., Shi L., Xiang B., Lu J., Wang L., Li D., Tang H., Li G. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis 2010, 31:559-566.
150. Shi W., Alajez N.M., Bastianutto C., Hui A.B., Mocanu J.D., Ito E., Busson P., Lo K.W., Ng R., Waldron J., O'Sullivan B., Liu F.F. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int. J. Cancer 2010, 126:2036-2048.
151. Alajez N.M., Lenarduzzi M., Ito E., Hui A.B., Shi W., Bruce J., Yue S., Huang S.H., Xu W., Waldron J., O'Sullivan B., Liu F.F. miR-218 Suppresses Nasopharyngeal Cancer Progression Through Downregulation Of Survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011, 71:2381-2391.
152. Ji Y., He Y., Liu L., Zhong X. MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett. 2010, 584:961-967.
153. Li G., Wu Z., Peng Y., Liu X., Lu J., Wang L., Pan Q., He M.L., Li X.P. MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett. 2010, 299:29-36.
154. Li G., Li X.P., Jiang L., Lu J., Liu X., Chen S.J. Silencing of COX-2 in nasopharyngeal carcinoma cells with a shRNAmir lentivirus vector. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:1111-1114.
155. Qu Y., Zhao S., Hong J., Tang S. Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase. J. Cancer Res. Clin. Oncol. 2009, 136:953-959.
156. Gourzones C., Gelin A., Bombik I., Klibi J., Verillaud B., Guigay J., Lang P., Temam S., Schneider V., Amiel C., Baconnais S., Jimenez A.S., Busson P. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol. J. 2010, 7:271.
157. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., de Gruijl T.D., Wurdinger T., Middeldorp J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6328-6333.
158. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
159. Hayward S.D., Liu J., Fujimuro M. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci. STKE 2006, 2006:re4.